 |
| Why do trade-offs and challenges persist in hemophilia A despite advancements? |
|
 |
| Leading HCPs who treat hemophilia A—and people who live with it—have a lot to say about the current state of hemophilia A care. |
| Bringing together healthcare providers, a pharmacist, and a person living with hemophilia A to share their unique perspectives on the state of hemophilia A care, this video discusses unmet needs, hidden trade-offs, and the potential benefits of increasing shared decision-making. |
| See how your peers are approaching hemophilia A discussions — and compare them with your own perspectives. |
|
Watch the video
|
|
 |
| What other topics are driving conversations? |
| Your peers in hemophilia A are also discussing these topics, including: |
 |
|
Why do bleeds persist despite prophylaxis therapy? |
|
|
Do patients want less frequent dosing options? |
|
|
Which patients might be dissatisfied with treatment? |
|
|
What trade-offs in administration preferences and bleed protection are patients making? |
|
|
| Could their opinions offer you a fresh perspective? |
|
Explore peer views
|
 |
| Stay current with the latest info |
| The world of hemophilia A treatment is changing. Get updates and communications from Novo Nordisk as they become available. |
|
Sign up
|
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-877-744-2579. |
|
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2026 Novo Nordisk All rights reserved. US26HRBD00113 July 2026 |
 |
|
|
|